芦可替尼联合阿扎胞苷治疗骨髓增生异常综合征/骨髓增殖性肿瘤的II期试验
这项II期试验评估芦可替尼联合阿扎胞苷治疗MDS/MPN患者,35例可评估患者中20例(57%)达到ICP MDS/MPN缓解,联合方案耐受性良好,MDS/MPN-U患者中位生存优于CMML和aCML。
要点
- 35例MDS/MPN患者接受芦可替尼联合阿扎胞苷治疗,20例(57%)达到ICP MDS/MPN缓解。
- 9例(45%)在加用阿扎胞苷后缓解,可触及脾肿大24周缩小>50%见于9/14(64%)。
- 新发3/4级贫血和血小板减少分别见于18例(51%)和19例(54%),仅1例(3%)需停药。
核心结论
- 芦可替尼联合阿扎胞苷耐受性良好,MDS/MPN患者ICP MDS/MPN缓解率为57%。
- 生存获益在MDS/MPN-U患者中最为突出。
研究设计与样本
- II期试验,35例MDS/MPN患者接受芦可替尼联合阿扎胞苷治疗。
- 芦可替尼按血小板计数确定剂量每日两次持续给药,28天为一周期,前3周期单用。
- 阿扎胞苷25 mg/m2(第1-5天)静注或皮下注射,推荐自第4周期起加入,为控制疾病可增至75 mg/m2(第1-5天)。
- 疾病快速增殖或原始细胞升高的患者可早于第4周期开始和/或更高剂量使用阿扎胞苷。
- 纳入MDS/MPN-U 14例、CMML 17例、aCML 4例,中位随访15.2个月(范围1.0-41.5)。
主要发现
- 全部患者可按2015年国际联盟MDS/MPN疗效标准(ICP MDS/MPN)评估,20例(57%)缓解。
- 9例(45%)在加用阿扎胞苷后缓解。
- 可触及脾肿大24周缩小>50%见于9/14(64%)患者。
- 缓解者较非缓解者更常见JAK2突变(P = .02)和脾肿大(P = .03)。
- MDS/MPN-U中位生存优于CMML和aCML(26.5 vs 15.1 vs 8个月;P = .034)。
关键数值与推荐
- 缓解评估采用2015年国际联盟MDS/MPN疗效标准(ICP MDS/MPN)。
- 芦可替尼剂量依据血小板计数确定,每日两次,28天为一周期。
- 阿扎胞苷25 mg/m2(第1-5天),可增至75 mg/m2(第1-5天)。
临床怎么用
- 芦可替尼联合阿扎胞苷在MDS/MPN患者中耐受性良好,ICP MDS/MPN缓解率为57%。
- 生存获益在MDS/MPN-U患者中最为突出。
- 新发3/4级贫血和血小板减少分别见于18例(51%)和19例(54%),仅1例(3%)需停药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ruxolitinib and azacytidine target distinct disease manifestations of myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs). Patients with MDS/MPNs initially received ruxolitinib BID (doses based on platelets count), continuously in 28-day cycles for the first 3 cycles. Azacytidine 25 mg/m2 (Day 1-5) intravenously or subcutaneously was recommended to be added to each cycle starting cycle 4 and could be increased to 75 mg/m2 (Days 1-5) for disease control. Azacytidine could be started earlier than cycle 4 and/or at higher dose in patients with rapidly proliferative disease or with elevated blasts. Thirty-five patients were treated (MDS/MPN-U, n =14; CMML, n =17; aCML, n =4), with a median follow-up of 15.2 months (range, 1.0-41.5). All patients were evaluable by the 2015 international consortium proposal of response criteria for MDS/MPNs (ICP MDS/MPN) and 20 (57%) responded. Nine patients (45%) responded after the addition of azacytidine. A greater than 50% reduction in palpable splenomegaly at 24 weeks was noted in 9/14 (64%) patients. Responders more frequently were JAK2-mutated (P = .02) and had splenomegaly (P = .03) compared to nonresponders. New onset grade 3/4 anemia and thrombocytopenia occurred in 18 (51%) and 19 (54%) patients, respectively, but required therapy discontinuation in only 1 (3%) patient. Patients with MDS/MPN-U had better median survival compared to CMML and aCML (26.5 vs 15.1 vs 8 months; P = .034). The combination of ruxolitinib and azacytidine was well-tolerated with an ICP MDS/MPN-response rate of 57% in patients with MDS/MPNs. The survival benefit was most prominent in patients with MDS/MPN-U.
引用
- Assi R, Kantarjian HM, Garcia-Manero G, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2017. PMID: 29134664. doi:10.1002/ajh.24972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。